Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
9.55
+1.54 (19.23%)
At close: Mar 9, 2026, 4:00 PM EDT
9.50
-0.05 (-0.52%)
After-hours: Mar 9, 2026, 6:10 PM EDT
CRBP Employees
Corbus Pharmaceuticals Holdings had 28 employees as of December 31, 2024. The number of employees increased by 9 or 47.37% compared to the previous year.
Employees
28
Change (1Y)
9
Growth (1Y)
47.37%
Revenue / Employee
n/a
Profits / Employee
-$2,804,893
Market Cap
176.95M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 341 |
| Sangamo Therapeutics | 183 |
| Innate Pharma | 174 |
| Zentalis Pharmaceuticals | 166 |
| Fate Therapeutics | 161 |
| Artiva Biotherapeutics | 106 |
| Rani Therapeutics Holdings | 106 |
| Immunic | 90 |
CRBP News
- 10 hours ago - Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 25 days ago - Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference - GlobeNewsWire
- 7 weeks ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript - Seeking Alpha
- 3 months ago - Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 - GlobeNewsWire
- 4 months ago - Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire